Can Exercise-Powered immune cells stop leukemia from coming back?

NCT ID NCT07254793

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized cells to prevent relapse, while others will get them to treat minimal residual disease or active relapse. The goal is to see if these cells are safe and more effective than standard donor lymphocyte infusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
exercise-mobilized NK-enriched donor lymphocyte infusions (DLI-X)
What this could lead to
If successful, this approach could offer a safer and more effective way to prevent or treat leukemia relapse after stem cell transplant, potentially improving survival and quality of life.
What could go wrong
This is a very early first-in-human trial with a small number of participants. The treatment may not work as hoped, and there are risks of graft-versus-host disease or other serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Arizona Cancer Center

    Tucson, Arizona, 85719, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.